Design and Synthesis of Liposomal Vancomycin and Evaluation of its Antibacterial Effects on Methicillin-Resistant Staphylococcus aureus

Document Type : Original article

Authors

1 Msc in Microbial Biotechnology, Department of Biology, Faculty of Basic Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran

2 Assistance Professor, Department of Biology, Faculty of Basic Science, Central Tehran Branch, Islamic Azad University, Tehran, Iran

Abstract

Introduction: Liposomes, as nanocarriers, have developed advanced systems for transporting biological molecules, such as vaccine adjuvants, anti-cancer drugs, antifungals, and painkillers. In this study, liposomal vancomycin was prepared and its antimicrobial effect on methicillin-resistant Staphylococcus aureus (MRSA), as one of the most important nosocomial infections, was investigated.
Materials and Methods: Liposomes were prepared using hydration and dehydration methods. Their surface morphology was measured using a scanning electron microscope (SEM), medium size of DLS (Dynamic Light Scattering), zeta potential, liposome stability, and drug loading rate. Antimicrobial effects and minimum inhibitory concentration (MIC) were performed using disc diffusion and microdilution methods, respectively, and the results were compared with the original form of the drug.
Results: Liposomal vancomycin was performed in several syntheses with DSPC:DCP: Cholesterol ratio, which showed the best result with a ratio of 7:2:1. Its size was reported with 154 nm in DLS and 100 nm in SEM. The drug loading rate was 61.6% and liposome stability was 30 days. The mean diameter of non-growth halos in the samples was 19.44 mm in free form and 22.7 mm in liposomal form. The MIC of free form was 1.2 mg/ml and liposomal form was 4.27 mg/ml.
Conclusion: The results indicated that the liposomal vancomycin form was stable for up to 30 days and its antimicrobial effects showed better results than the free vancomycin form against the MRSAs isolated from the hospital.

Keywords

References

  1. Patel V. Liposome: a novel carrier for targeting drug delivery system. Asian J Pharm Res Dev. 2020; 8(4):67-76.
  2. Eroğlu İ, İbrahim M. Liposome-ligand conjugates: a review on the current state of art. J Drug Target. 2020; 28(3):225-44.
  3. Singh LD, Ganju K, Rajpoot R. Review on liposome as novel approach for cancer therapy. Asian J Pharm Res Dev. 2020; 8(3):122-9.
  4. Chauhan SB, Gupta V. Recent advances in liposome. Res J Pharm Technol. 2020; 13(4):2053-6.
  5. Patel V. Liposome: a novel carrier for targeting drug delivery system. Asian J Pharm Res Dev. 2020; 8(4):67-76.
  6. Singh S, Sharma N, Grover R, Grewal IK. Liposome-based drug delivery system for cancer chemo-therapeutics. Plant Arch. 2020; 20(1):3305-15.
  7. Choudhury A, Sonowal K, Laskar RE, Deka D, Dey BK. Liposome: a carrier for effective drug delivery. J Appl Pharm Res. 2020; 8(1):22-8.
  8. Catania R, Maguire O, Moore C, Falcone FH, Chan W, Mantovani G, et al. Functionalised liposomal formulations for delivery of antibiotic agents. Access Microbiol. 2019; 1(1A):788.
  9. Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017; 9(1):e1416.
  10. Priyanka R, Bhattacharyya S. A review on promising antibiotic therapy by novel delivery systems. Asian J Pharm Clin Res. 2018; 11(5):18-24.
  11. Dezfulian A, Aslani MM, Oskoui M, Farrokh P, Azimirad M, Dabiri H, et al. Identification and characterization of a high vancomycin-resistant staphylococcus aureus harboring VanA gene cluster isolated from diabetic foot ulcer. Iran J Basic Med Sci. 2012; 15(2):803-6.
  12. Luque Y, Louis K, Jouanneau C, Placier S, Esteve
    E, Bazin D, et al. Vancomycin-associated cast nephropathy. J Am Soc Nephrol. 2017; 28(6):1723-8.
  13. Erickson LL, Nelson T, Oakes JM. Hospital policies related to transmission of methicillin-resistant staphylococcus aureus (MRSA). Infect Cont Hosp Epidemiol. 2020; 41(S1):s252-3.
  14. Mairi A, Touati A, Lavigne JP. Methicillin-Resistant Staphylococcus aureus ST80 Clone: a systematic review. Toxins. 2020; 12(2):119.
  15. Galar A, Weil AA, Dudzinski DM, Muñoz P, Siedner MJ. Methicillin-resistant Staphylococcus aureus prosthetic valve endocarditis: pathophysiology, epidemiology, clinical presentation, diagnosis, and management. Clin Microbiol Rev. 2019; 32(2):
    e00041-18.
  16. Jani M, Sengupta S, Hu K, Azad RK. Deciphering pathogenicity and antibiotic resistance islands in methicillin-resistant Staphylococcus aureus genomes. Open Biol. 2017; 7(12):170094.
  17. Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018; 4(1):18033.
  18. Kalhapure RS, Suleman N, Mocktar C, Seedat N, Govender T. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J Pharm Sci. 2015; 104(3):872-905.
  19. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2):145-60.
  20. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; 8(1):102.
  21. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop J Pharm Res. 2013; 12(2):265-73.
  22. Trucillo P. Drug Carriers: Classification, Administration, Release Profiles, and Industrial Approach. Processes. 2021; 9(3):470.
  23. Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016; 23(9):3319-29.
  24. Wibroe PP, Ahmadvand D, Oghabian MA, Yaghmur A, Moghimi SM. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome. J Control Release. 2016; 221:1-8.
  25. Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome®): a review of
    the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016; 76(4):485-500.
  26. Tam V, Chow D, He J. Liposomal formulations of polymyxin and uses thereof. Washington, D.C: United States Patent US; 2017.
  27. Pushparaj Selvadoss P, Nellore J, Balaraman Ravindrran M, Sekar U, Tippabathani J. Enhancement of antimicrobial activity by liposomal oleic acid-loaded antibiotics for the treatment of multidrug-resistant Pseudomonas aeruginosa. Artif Cells Nanomed Biotechnol. 2018; 46(2):268-73.
  28. Gonda I, Blanchard J, Cipolla DC, Bermudez LE. Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria. Washington, D.C: United States Patent US; 2019.
  29. Kebriaei R, Bhise K, Sau S, Rice S, Stamper K, Iyer A, et al. Liposomal vancomycin and cefazolin combinations for S. aureus biofilms. Open Forum Infect Dis. 2018; 5(Suppl 1):S713.
  30. Hajiahmadi F, Alikhani MY, Shariatifar H, Arabestani MR, Ahmadvand D. The bactericidal effect of liposomal vancomycin as a topical combating system against Methicillin-resistant Staphylococcus aureus skin wound infection in mice. Med J Islam Republ Iran. 2019; 33(1):941-7.
  31. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007; 4(4):297-305.
  32. Garg T, K Goyal A. Liposomes: targeted and controlled delivery system. Drug Deliv Lett. 2014; 4(1):62-71.
  33. Luo D, Li N, Carter KA, Lin C, Geng J, Shao S, et al. Rapid light‐triggered drug release in liposomes containing small amounts of unsaturated and porphyrin–phospholipids. Small. 2016; 12(22):3039-47.
  34. Marqués-Gallego P, de Kroon AI. Ligation strategies for targeting liposomal nanocarriers. Biomed Res Int. 2014; 2014:129458.
  35. Müller M, Mackeben S, Müller-Goymann CC. Physicochemical characterisation of liposomes with encapsulated local anaesthetics. Int J Pharm. 2004; 274(1-2):139-48.
  36. Mandan S, Chavan M, Bhadane Y, Kalal C. Nanosponges: a new drug delivery system. J Drug Deliv Ther. 2018; 8(6-A):141-3.
  37. Sujitha S, Dinesh P, Rasool M. Berberine encapsulated PEG-coated liposomes attenuate Wnt1/β-catenin signaling in rheumatoid arthritis via miR-23a activation. Eur J Pharm Biopharm. 2020; 149:170-91.
  38. Serri A, Mahboubi A, Zarghi A, Moghimi H. Investigating the antimicrobial efficacy of liposomal vancomycin in gram-positive and gram-negative bacteria-a preliminary mechanistic study. Iran J Pharm Sci. 2018; 14(3):13-24.

Navid No
Volume 24, Issue 77
June 2021
Pages 20-40

Files

Share

How to cite

Statistics